Xingputai Completes Tens of Millions RMB Strategic+ Financing to Advance AI and Advanced Manufacturing Solutions Across Industries

Recently, SPACE PEPTIDES PHARMACEUTICAL (TAIZHOU) CO., LTD. (hereinafter referred to as “Xingputai”) announced the completion of its strategic+ round financing, amounting to tens of millions of RMB. This round was jointly invested by Jiangsu Taifeng Chemical Co., Ltd., a global leader in the dye industry, and Fengtai Enterprise Management, with Yuanyi Capital serving as the exclusive financial advisor for this financing round. Through this financing, Jiangsu Taifeng and Xingputai will fully leverage their respective advantages and resources to jointly support Xingputai’s sustained and stable development in the Taixing Economic Development Zone. Both parties will also collaboratively explore and facilitate the smooth implementation and commercial operation of cooperative projects.

Founded in September 2019, Xingputai is located in the Taixing Economic Development Zone, one of China’s top ten chemical industrial parks. With a total investment of RMB 1.03 billion and covering an area of 120 mu, the company has been included in the National Major Construction Project Database. Co-founded by multiple scientists from China and abroad in the fields of AI, intelligent manufacturing, and pharmaceuticals, its founders include Dr. He Runze, a Jiangsu Province “Shuangchuang Doctor,” a leading entrepreneurial talent under Xiamen City’s “Double Hundred Plan,” and a Shanghai Pujiang Talent; Professor Jean-Louis Reymond, Head of the Department of Chemistry at the University of Bern, Deputy Director Scientist of the Swiss National Competence Center, and founder of the Chemical Space theory; and Professor Hong Wenjing, a National Distinguished Young Scholar, Nanqiang Distinguished Professor at Xiamen University, and Deputy Dean of the College of Chemistry and Chemical Engineering. The group has established joint laboratories at Xiamen University and the University of Bern to continuously enhance its R&D capabilities. By leveraging its proprietary Chemical Space technology for novel drug discovery, the company has resolved critical bottlenecks in global peptide drug discovery, enabling the rapid and precise identification and delivery of innovative peptide drug molecules within 3–6 months, thereby significantly reducing R&D cycles, costs, and risks.

SPACE PEPTIDES aligns itself with the key priorities outlined in the "Made in China 2025" strategic plan. The company has developed a portfolio of innovative peptide drugs with independent intellectual property rights, spanning therapeutic areas such as anti-infectives, ophthalmology, weight management, diabetes, and central nervous system disorders. SPACE PEPTIDES provides integrated R&D and manufacturing services to global clients in the innovative peptide drug sector, achieving large-scale commercial implementation. It has established collaborative partnerships with leading domestic and international pharmaceutical enterprises, listed companies, and Fortune Global 500 corporations. Furthermore, since its inception, SPACE PEPTIDES has actively explored how AI and advanced manufacturing can empower traditional industries. Leveraging the Chemical Space theory, which is underpinned by over 20 years of data accumulation and AI training in Switzerland, the company continues to enhance its cross-industry AI and advanced manufacturing solutions. It is also exploring industrial applications across multiple sectors, including pharmaceuticals, chemicals, agriculture, cosmetics, and flavors and fragrances.

Dr. He Runze, Chairman of SPACE PEPTIDES PHARMACEUTICAL (TAIZHOU) CO., LTD., stated“It is a great honor for SPACE PEPTIDES to secure investment from industry leaders such as Jiangsu Taifeng, following the earlier investment from Xingqi Eye Medicine mid-year. Since its inception, SPACE PEPTIDES has been committed to providing integrated R&D and manufacturing services to global customers of innovative peptide drugs, achieving rapid growth with strong support from the Taizhou Municipal Government, the Taixing Economic Development Zone, and leading local enterprises. Through this collaboration with Jiangsu Taifeng, both parties will fully integrate their respective advantageous resources to promote the further development of SPACE PEPTIDES in the Taixing Economic Development Zone. Additionally, both sides will actively explore the application of AI and advanced manufacturing solutions in the dye industry, facilitating the implementation of new quality productive forces in this sector.”

Jiangsu Taifeng stated:“Since its establishment over thirty years ago, Jiangsu Taifeng Chemical Co., Ltd. has consistently adhered to a business philosophy of pursuing excellence and sustainability, committing to green and technological development while continuously building the company’s green competitiveness. Jiangsu Taifeng highly recognizes the outstanding achievements made by Xingputai since its inception five years ago. Through this investment in Xingputai, both parties will join hands to promote the advancement and implementation of a series of strategic cooperation projects, actively exploring new directions for green, low-carbon, and high-quality development in the dye industry. They strive to serve as pioneers and forerunners in the intelligent transformation of China’s chemical industry, while also actively collaborating with Fengtai Enterprise Management to facilitate the application of AI and advanced manufacturing in their portfolio companies.”

Jiangsu Taifeng Chemical Co., Ltd. is headquartered in the Hongqiao Industrial Park of Taixing, Jiangsu Province, and stands as the world’s largest producer and distributor of indigo. Its production base is located in the High-Tech Development Zone of Alxa Left Banner. Specializing in the manufacture and sales of vat indigo series products, the company leverages its core business to integrate advantageous resources, build a comprehensive product industry chain, and pursue diversified investments, thereby continuously enhancing its overall competitiveness. After nearly 30 years of development, Taifeng Chemical has ranked first in the global indigo industry for eighteen consecutive years, with a market share exceeding 50% for ten straight years. Its products are widely sold across Central and South America, the European Union, and various countries and regions in Southeast Asia.

To achieve the high-tech transformation of traditional industries and realize strategic transition, the company established an Academician Workstation in August 2020 in collaboration with Academician Li Yadong from the Department of Chemistry at Tsinghua University. It has actively invested in fields such as new OLED materials (Xiahe Technology), single-atom catalysis (Beijing Single-Atom Catalysis), and biopharmaceuticals (Fushi Biotechnology, Guanyu Biotechnology). The company maintains deep integration between its Academician Workstation and research institutions including the Taixing New Materials Research Institute, the Hefei Single-Atom New Materials Research Institute, and the Wuhu Innovation Research Institute. Placing high importance on innovation and the agglomeration effect of high-end talent, the company is jointly building a sci-tech innovation platform for academicians and expert teams with Taixing City.

Fengtai Enterprise Management is an investment management platform established by Jiangsu Taifeng, leveraging its Academician Workstation sci-tech innovation platform and integrating external resources. The platform brings together renowned domestic corporate management experts, executives from multinational corporations, and specialists in chemistry and chemical engineering, focusing on financial investment and resource empowerment in fields such as new materials.